Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. (TYRA), a Delaware corporation, filed this Current Report on Form 8-K on October 18, 2024. The company is an emerging growth company with its principal executive offices in Carlsbad, California. The report details a specific corporate transaction regarding unregistered sales of equity securities.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on a capital structure transaction.
Material Changes
On October 18, 2024, the Company entered into an exchange agreement with Boxer Capital, LLC and RA Capital Healthcare Fund, L.P. (collectively, the Holders). The material changes include:
- Boxer Capital: Exchanged 2,000,000 shares of Common Stock for pre-funded warrants to acquire 2,000,000 shares.
- RA Capital: Exchanged 1,000,000 shares of Common Stock for pre-funded warrants to acquire 1,000,000 shares.
- Total Exchange: 3,000,000 shares of Common Stock were exchanged for an equivalent number of pre-funded warrants.
- Warrant Terms: Each warrant has an exercise price of $0.001 per share, is immediately exercisable, and does not expire.
- Beneficial Ownership Limitations: Holders may not exercise warrants if it causes them to own more than 9.99% or 19.99% (as selected) of outstanding shares. Increases to this limit require a 61-day notice period.
- Closing Date: The exchange is expected to close on or before October 22, 2024.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard terms of the exchange agreement. The transaction relies on the exemption from registration under Section 3(a)(9) of the Securities Act of 1933. The filing notes that the description of the Exchange Warrants is qualified by reference to the full form of the warrant filed as Exhibit 4.1.
Investor Verification Checklist
- Verify the closing of the exchange transaction by October 22, 2024.
- Review Exhibit 4.1 (Form of Exchange Warrant) for complete terms and conditions.
- Monitor the Company's subsequent filings for the updated share count and capitalization table post-exchange.
- Confirm the specific beneficial ownership percentage (9.99% or 19.99%) selected by each Holder.